INTRODUCTION
The economic burden of chronic diseases is high due to the permanent disease's progression and the need of lifelong health care services. The economic burden of chronic diseases is divided by patients and their families, health insurance, state and society in different proportion.
Knowledge of the costs of an illness can help policy makers to decide which diseases need to be addressed first by health care and prevention policy. The micro-or macro-level decision of resource's allocation defines the distribution of economic burden among stakeholders. In the macro-level decision-making (e.g. allocation of resource of government budget among each sector) societal perspective is dominant. In the micro-level decisionmakers reflect them own budget from financer perspective.
Cost-of-illness (COI) studies aim to assess the economic burden of health problems on the population overall, and they are conducted for an ever widening range of health conditions and geographical settings. While they attract much interest from public health advocates and healthcare policy makers, inconsistencies in the way in which they are conducted and a lack of transparency in reporting have made interpretation difficult, and have ostensibly limited their usefulness. COI is able to evaluate the direct, indirect and intangible costs of a given disease in monetary terms in different perspectives (e.g. societal, public payer, patient, cross-national). Depending on perspective, it consists of different elements, and it values identical cost contents in different ways. The societal perspective takes account of all cost factors from the point of view. 
OBJECTIVES

METHODS
Direct costs are costs directly linked to the treatment, detection, prevention or care of an illness. They are further separated into medical cost, i.e. costs that occur in the health care sector, and non-medical costs that occur in other sectors, such as social services, community or patients themselves.
Other nonmedical costs such transportation, social services, etc are integrated into direct costs.
Indirect costs are production losses that result as a consequence of an illness, premature death or treatment of an illness. These definitions are used in most studies, but there is some discussion as to whether informal care should be considered a direct or an indirect cost. Informal care costs can be estimated in three different ways: production losses for those carers who work, replacement cost using as proxy the cost of professional carers, or loss of leisure time for all carers.
The potential applicability of COI in societal perspective is analyzed with the comparison of indirect cost value and ratio among Hungarian RA patients from COI studies with different design and data resources. The value and ratio of indirect cost of RA in Hungary was estimated in three different methodological approaches: 1. Systematic literature research on PubMed database at 2011.02.01.
2.
Estimation from public macro data -'top down'. The top-down approach measures the proportion of a disease that is due to exposure to the disease or risk factor. 3.
Questionnaire survey was conducted among Hungarian RA patients with societal perspective -'botton up'. The bottom-up approach estimates costs by calculating the average cost of treatment of the illness and multiplying it by the prevalence of the illness. Estimation from micro sources.
RESULTS
Based on the systematic literature research there were 357 findings for "Rheumatoid arthritis AND cost of illness". After multiple selections 12 relevant articles were involved. Studies used a wide range of sources (patient interviews, local register, hospital data or clinical study reports), which resulted a strong limitation of comparison or meta-analysis. An international analysis Kobelt et al [1] found the most relevant for an international comparison, where based on epidemiology and macro data estimated average cost of RA. Figure 1 shows, there is a wide range in Europe on the average cost pro patient in the amounts (3 700 -15 000 €) and also in the structure of costs elements (i.e. informal costs: 30-43%). The cost analysis was undertaken for Hungary as well, and the informal costs found on a relatively high proportion. The prevalence was found 37 907 patients and the indirect and informal care's costs were found 837 € and 2 237 € at 2008. With the second 'top-down' approach the costs of RA were defined from different public sources. Direct medical costs were clarified on the National Health Insurance Fund and Administration (NHIFA) database. NHIFA database uniquely includes health care utilization data (pharmaceutical, inand outpatient care services, labs, diagnostics, medical aids, sickness benefit) of the total population of Hungary. Since 2004, all financed health care services are strictly validated and use the same database structure. The representative data base covers the 10 million whole Hungarian populations. Disability pension because of early retirement was specified on the published sources of the Central Administration of National Pension Insurance (CANPI) and the National Rehabilitation and Social Affairs Office (NRSAO). [2] [3] Estimated average cost of early retirement was calculated with the average amounts of early retirements from CANPI and RA specific prevalence was established from the NRSAO database. Results demonstrated a much lower value for non-direct cost than it was established by Kobelt. At NHIFA financing database 44 129 subjects were detected. The cost of sickness benefit was only 48 €, while the estimated costs of early retirement found between on a quiet wild range (291 -550 €). These non-direct costs represent a payers' perspective and explain the lower values.
Finally with the third 'bottom-up' approach the questionnaire survey was undertaken at 2011. 123 patients filled in our questionnaire form. Patients were managed by Patient Organizations. Subject did not receive any honorary. The comparison of the listed resources alongside identical dimensions indicates that the tendencies are similar although there are significant differences in the order of magnitude. It is hard to compare the results of the three different methodological approaches, because of significant differences on the amount. Different approaches could eventuate a wild scope of answers, even if they used the same sources.
CONCLUSIONS
Decisions about healthcare resource allocations affect social welfare. In reimbursement decisions the NHIFA uses the financer perspective, but in the ranking and evaluation of health technologies and therapies the societal perspective represents the basis for optimization. In Europe pharmacoeconomic guidelines are commonly used and widespread, and declare all relevant parameter-selection and modeling criteria. COI studies can help in the identification of decision-making focal points, although this necessitates the assessment and standardization of the applicable methodologies.
